High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire

PLoS Pathog. 2022 Nov 28;18(11):e1010999. doi: 10.1371/journal.ppat.1010999. eCollection 2022 Nov.

Abstract

Antibodies targeting the human malaria parasite Plasmodium falciparum circumsporozoite protein (PfCSP) can prevent infection and disease. PfCSP contains multiple central repeating NANP motifs; some of the most potent anti-infective antibodies against malaria bind to these repeats. Multiple antibodies can bind the repeating epitopes concurrently by engaging into homotypic Fab-Fab interactions, which results in the ordering of the otherwise largely disordered central repeat into a spiral. Here, we characterize IGHV3-33/IGKV1-5-encoded monoclonal antibody (mAb) 850 elicited by immunization of transgenic mice with human immunoglobulin loci. mAb 850 binds repeating NANP motifs with picomolar affinity, potently inhibits Plasmodium falciparum (Pf) in vitro and, when passively administered in a mouse challenge model, reduces liver burden to a similar extent as some of the most potent anti-PfCSP mAbs yet described. Like other IGHV3-33/IGKV1-5-encoded anti-NANP antibodies, mAb 850 primarily utilizes its HCDR3 and germline-encoded aromatic residues to recognize its core NANP motif. Biophysical and cryo-electron microscopy analyses reveal that up to 19 copies of Fab 850 can bind the PfCSP repeat simultaneously, and extensive homotypic interactions are observed between densely-packed PfCSP-bound Fabs to indirectly improve affinity to the antigen. Together, our study expands on the molecular understanding of repeat-induced homotypic interactions in the B cell response against PfCSP for potently protective mAbs against Pf infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Protozoan
  • Cryoelectron Microscopy
  • Humans
  • Malaria Vaccines*
  • Malaria* / parasitology
  • Malaria, Falciparum* / parasitology
  • Mice
  • Mice, Transgenic
  • Plasmodium falciparum
  • Protozoan Proteins

Substances

  • Protozoan Proteins
  • Antibodies, Monoclonal
  • Antibodies, Protozoan
  • Malaria Vaccines

Grants and funding

This work was undertaken, in part, thanks to funding from the Bill and Melinda Gates Foundation (INV-008866; J.P.J., H.W. and E.A.L., OPP1159947; S.B., P.K., INV-008612; G.D.T.) and was supported by the CIFAR Azrieli Global Scholar program (J.P.J.), the Ontario Early Researcher Award program (J.P.J.), and the Canada Research Chair program (J.L.R., J.P.J.). I.K. was supported by a SickKids Restracomp Fellowship. E.T. was supported by a Vanier Canada Graduate Scholarship. S.W.S. was supported by a SickKids Lap-Chee Tsui Postdoctoral Fellowship and a CIHR fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.